In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines

Wang,Min‑Cong; Liang,Xuan; Liu,Zhi‑Yan; Cui,Jie; Liu,Ying; Jing,Li; Jiang,Li‑Li; Ma,Jie‑Qun; Han,Li‑Li; Guo,Qian‑Qian; Yang,Cheng‑Cheng; Wang,Jing; Wu,Tao; Nan,Ke‑Jun; Yao,Yu

doi:10.3892/or.2014.3583

In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines

Authors:
- Min‑Cong Wang
- Xuan Liang
- Zhi‑Yan Liu
- Jie Cui
- Ying Liu
- Li Jing
- Li‑Li Jiang
- Jie‑Qun Ma
- Li‑Li Han
- Qian‑Qian Guo
- Cheng‑Cheng Yang
- Jing Wang
- Tao Wu
- Ke‑Jun Nan
- Yu Yao
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital, College of Medicine of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China
Published online on: November 3, 2014 https://doi.org/10.3892/or.2014.3583
Pages: 239-249

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The concurrent administration of chemotherapy and epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) has previously produced a negative interaction and failed to confer a survival benefit to non‑small cell lung cancer (NSCLC) patients compared with first‑line cytotoxic chemotherapy. The present study aimed to investigate the optimal schedule of the combined treatment of cisplatin/paclitaxel and icotinib in NSCLC cell lines and clarify the underlying mechanisms. HCC827, H1975, H1299 and A549 human NSCLC cell lines with wild‑type and mutant EGFR genes were used as in vitro models to define the differential effects of various schedules of cisplatin/paclitaxel with icotinib treatments on cell growth, proliferation, cell cycle distribution, apoptosis, and EGFR signaling pathway. Sequence‑dependent antiproliferative effects differed among the four NSCLC cell lines, and were not associated with EGFR mutation, constitutive expression levels of EGFR or downstream signaling molecules. The antiproliferative effect of cisplatin plus paclitaxel followed by icotinib was superior to that of cisplatin or paclitaxel followed by icotinib in the HCC827, H1975, H1299 and A549 cell lines, and induced more cell apoptosis and G0/G1 phase arrest. Cisplatin and paclitaxel significantly increased the expression of EGFR phosphorylation in the HCC827 cell line. However, only paclitaxel increased the expression of EGFR phosphorylation in the H1975 cell line. Cisplatin/paclitaxel followed by icotinib influenced the expression of p‑EGFR and p‑AKT, although the expression of p‑ERK1/2 remained unchanged. The results suggest that the optimal schedule of the combined treatment of cisplatin/paclitaxel and icotinib differed among the NSCLC cell lines. The results also provide molecular evidence to support clinical treatment strategies for NSCLC patients.

View Figures

View References

1	Jemal A, Thun MJ, Ries LA, et al: Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 100:1672–1694. 2008. View Article : Google Scholar : PubMed/NCBI
2	Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar
3	Salama JK and Vokes EE: New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol. 31:1029–1038. 2013. View Article : Google Scholar : PubMed/NCBI
4	Xu Y, Zhang Y and Ma S: EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer. 73:249–255. 2011. View Article : Google Scholar : PubMed/NCBI
5	Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med. 346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
6	Smit EF, van Meerbeeck JP, Lianes P, et al: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol. 21:3909–3917. 2003. View Article : Google Scholar : PubMed/NCBI
7	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
8	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
9	Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004. View Article : Google Scholar
10	Brandao GD, Brega EF and Spatz A: The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. Curr Oncol. 19(Suppl 1): S24–S32. 2012. View Article : Google Scholar : PubMed/NCBI
11	Mitsudomi T and Yatabe Y: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 277:301–308. 2010. View Article : Google Scholar
12	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
13	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
14	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
15	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
16	Mok TS, Wu YL, Yu CJ, et al: Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 27:5080–5087. 2009. View Article : Google Scholar : PubMed/NCBI
17	Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol. 22:777–784. 2004. View Article : Google Scholar : PubMed/NCBI
18	Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI
19	Herbst RS, Prager D, Hermann R, et al: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 23:5892–5899. 2005. View Article : Google Scholar : PubMed/NCBI
20	Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH and Gandara DR: Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 7:385–388. 2006. View Article : Google Scholar : PubMed/NCBI
21	Gandara DR and Gumerlock PH: Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol. 23:5856–5858. 2005. View Article : Google Scholar : PubMed/NCBI
22	Normanno N: Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination? J Clin Oncol. 23:928–930. 2005. View Article : Google Scholar : PubMed/NCBI
23	Baselga J: Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J Clin Oncol. 22:759–761. 2004. View Article : Google Scholar : PubMed/NCBI
24	Milano G, Spano JP and Leyland-Jones B: EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. Br J Cancer. 99:1–5. 2008. View Article : Google Scholar : PubMed/NCBI
25	Zhao Q, Shentu J, Xu N, et al: Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 73:195–202. 2011. View Article : Google Scholar
26	Shi Y, Zhang L, Liu X, et al: Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 14:953–961. 2013. View Article : Google Scholar : PubMed/NCBI
27	Xu JM, Azzariti A, Colucci G and Paradiso A: The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol. 52:442–448. 2003. View Article : Google Scholar : PubMed/NCBI
28	Cheng H, An SJ, Dong S, et al: Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. J Hematol Oncol. 4:52011. View Article : Google Scholar : PubMed/NCBI
29	Cheng H, An SJ, Zhang XC, et al: In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemother Pharmacol. 67:637–646. 2011. View Article : Google Scholar
30	Tsai CM, Chen JT, Stewart DJ, et al: Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed? J Thorac Oncol. 6:559–568. 2011. View Article : Google Scholar : PubMed/NCBI
31	Gandara D, Narayan S, Lara PN Jr, et al: Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 11:5057s–5062s. 2005. View Article : Google Scholar : PubMed/NCBI
32	Li T, Ling YH, Goldman ID and Perez-Soler R: Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 13:3413–3422. 2007. View Article : Google Scholar : PubMed/NCBI
33	Gumerlock PH, Pryde BJ, Kimura T, et al: Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma (NSCLC). J Clin Oncol. 22:26612003.
34	Mahaffey CM, Davies AM, Lara PN Jr, et al: Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 8:548–553. 2007. View Article : Google Scholar
35	Stewart DJ, Raaphorst GP, Yau J and Beaubien AR: Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs. 14:115–130. 1996. View Article : Google Scholar : PubMed/NCBI
36	Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 63:12–31. 2007. View Article : Google Scholar : PubMed/NCBI
37	Hall MD, Okabe M, Shen DW, Liang XJ and Gottesman MM: The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 48:495–535. 2008. View Article : Google Scholar
38	Stewart DJ: Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
39	Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006. View Article : Google Scholar : PubMed/NCBI
40	Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. New Engl J Med. 358:1160–1174. 2008. View Article : Google Scholar : PubMed/NCBI
41	Van Schaeybroeck S, Kyula J, Kelly DM, et al: Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther. 5:1154–1165. 2006. View Article : Google Scholar : PubMed/NCBI